Organogenesis Holdings Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ORGO$0.94+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(18,843) | $(2,100) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 3,444 | 3,072 |
| Amortization of intangible assets | 842 | 901 |
| Reduction in the carrying value of right-of-use assets | 1,997 | 2,203 |
| Non-cash interest expense | 69 | 105 |
| Deferred interest expense | — | 122 |
| Deferred tax benefit | (1,266) | — |
| Provision recorded for credit losses | 873 | 968 |
| Loss on disposal of property and equipment | 19 | 347 |
| Adjustment for excess and obsolete inventories | 3,709 | 2,515 |
| Stock-based compensation | 3,367 | 2,407 |
| Write-down to fair value for asset held for sale | 6,567 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 5,668 | (15,117) |
| Inventories | (8,732) | (4,670) |
| Prepaid expenses and other current assets and other assets | (5,123) | (4,315) |
| Operating leases | (2,037) | (2,199) |
| Accounts payable | (2,496) | (4,391) |
| Accrued expenses and other liabilities | (7,993) | 9,990 |
| Net cash used in operating activities | (19,935) | (10,162) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (3,626) | (2,222) |
| Net cash used in investing activities | (3,626) | (2,222) |
| Cash flows from financing activities: | ||
| Payments of term loan under the 2021 Credit Agreement | — | (1,406) |
| Payments of withholding taxes in connection with RSUs vesting | (1,796) | (1,120) |
| Proceeds from the exercise of stock options | 25 | 180 |
| Principal repayments of finance lease obligations | (285) | (262) |
| Net cash used in financing activities | (2,056) | (2,608) |
| Change in cash, cash equivalents and restricted cash | (25,617) | (14,992) |
| Cash, cash equivalents, and restricted cash, beginning of period | 136,151 | 104,338 |
| Cash, cash equivalents, and restricted cash, end of period | $110,534 | $89,346 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $— | $1,375 |
| Cash paid for income taxes | $150 | $35 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | $2,748 | $— |
| Purchases of property and equipment included in accounts payable and accrued expenses | $172 | $786 |
| Right-of-use assets obtained through operating lease obligations | $1,642 | $701 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.